Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| KPV | Thymosin Alpha-1 | |
|---|---|---|
| Category | Peptides | Growth Factors |
| Standard Dose | Research indicates 200-500 mcg daily via subcutaneous injection, or 500 mcg-1 mg orally for gut-targeted inflammation. | Research indicates 1.6 mg administered twice weekly via subcutaneous injection. |
| Timing | Oral dosing on empty stomach for gut-targeted effects. No strict timing for subcutaneous. | Morning administration preferred. No food timing restrictions. |
| Cycle Duration | 4-12 weeks. Oral protocols for gut inflammation may extend longer under supervision. | 8-12 week cycles, with periodic breaks. Some protocols use continuous low-dose maintenance. |
| Evidence Level | animal_plus_anecdotal | strong_human |
KPV (Lysine-Proline-Valine) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) that inhibits NF-kB signaling through a non-melanocortin receptor-mediated mechanism. It is transported intracellularly via the PepT1 transporter, where it stabilizes IkB-alpha and suppresses nuclear translocation of p65RelA by competing with importin-beta at the armadillo domain 7 and 8 binding site. It also reduces MAPK inflammatory signaling and IL-8 secretion in intestinal epithelial cells.
Research indicates 200-500 mcg daily via subcutaneous injection, or 500 mcg-1 mg orally for gut-targeted inflammation.
Oral dosing on empty stomach for gut-targeted effects. No strict timing for subcutaneous.
4-12 weeks. Oral protocols for gut inflammation may extend longer under supervision.
Thymosin Alpha-1 is a 28-amino acid peptide naturally produced by the thymus that acts as a pleiotropic immune modulator through Toll-like receptors (TLR2, TLR3, TLR4, TLR7, TLR9) on myeloid and plasmacytoid dendritic cells. It activates downstream IRF3, NF-kB, p38MAPK, and MyD88 signaling pathways to promote cytokine production. It modulates TNF-alpha, IFN-gamma, and IL-2 in CD4+ and CD8+ T lymphocytes by upregulating CD40/CD40L and downregulating PD-L1/PD-1 expression, enhancing both innate and adaptive immunity.
Research indicates 1.6 mg administered twice weekly via subcutaneous injection.
Morning administration preferred. No food timing restrictions.
8-12 week cycles, with periodic breaks. Some protocols use continuous low-dose maintenance.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →